Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming

(2021) Yao Wang et al.   Nature Communications

Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models

(2020) Roland B. Walter et al.   BLOOD REVIEWS

CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions

(2020) Sherly Mardiana et al.   Frontiers in Oncology

Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells

(2020) Liangshun You et al.   Frontiers in Immunology

T cell receptor-engineered T cells for leukemia immunotherapy

(2019) Yikai Zhang et al.   Cancer Cell International

High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells

(2019) Synat Kang et al.   Frontiers of Medicine

T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant

(2019) Aude G. Chapuis et al.   NATURE MEDICINE

Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy

(2018) Desmond O. Acheampong et al.   BIOMEDICINE & PHARMACOTHERAPY

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

(2018) Joseph A. Fraietta et al.   NATURE MEDICINE

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

Mechanisms of immune escape after allogeneic hematopoietic cell transplantation

(2018) Robert Zeiser et al.   BLOOD

Lentiviral transduction of mammalian cells for fast, scalable and high-level production of soluble and membrane proteins

(2018) Jonathan Elegheert et al.   Nature Protocols

Isolation and characterization of NY-ESO-1–specific T cell receptors restricted on various MHC molecules

(2018) Michael T. Bethune et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

(2017) Terry J Fry et al.   NATURE MEDICINE

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy

(2016) Pragya Srivastava et al.   Oncotarget

Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies

(2016) Lorenz Jahn et al.   Oncotarget

Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy

(2015) Y. Arai et al.   BLOOD

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

(2015) Katherine B. Chiappinelli et al.   CELL

Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts

(2015) Pragya Srivastava et al.   Epigenetics

Selection bias: maintaining less-differentiated T cells for adoptive immunotherapy

(2015) Yang Xu et al.   JOURNAL OF CLINICAL INVESTIGATION

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

(2015) Aaron P Rapoport et al.   NATURE MEDICINE

Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing

(2015) Agnes S. Klar et al.   PLoS One

Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15

(2014) Y. Xu et al.   BLOOD

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

(2014) P. F. Robbins et al.   CLINICAL CANCER RESEARCH

Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia

(2014) A Baragaño Raneros et al.   GENES AND IMMUNITY

Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions

(2014) Paul F. Robbins et al.   JOURNAL OF IMMUNOLOGY

Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia

(2014) Sarah M. Leonard et al.   PLoS One

Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

(2014) K. Odunsi et al.   Cancer Immunology Research

Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation

(2013) Rainer Storb et al.   JOURNAL OF CLINICAL ONCOLOGY

The cancer-testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo

(2013) JIHAO ZHOU et al.   Molecular Medicine Reports

Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine

(2013) Yushi Yao et al.   PLoS One

Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity

(2012) Amir A. Toor et al.   BRITISH JOURNAL OF HAEMATOLOGY

Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells

(2012) Hsing-Chen Tsai et al.   CANCER CELL

Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors

(2012) Emmet McCormack et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Epigenetic Modulation to Enable Antigen-specific T-cell Therapy of Colorectal Cancer

(2012) Jeffrey Chou et al.   JOURNAL OF IMMUNOTHERAPY

Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia

(2011) Djordje Atanackovic et al.   AMERICAN JOURNAL OF HEMATOLOGY

Tumor Evasion from T Cell Surveillance

(2011) Katrin Töpfer et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

(2011) Paul F. Robbins et al.   JOURNAL OF CLINICAL ONCOLOGY

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors

(2011) S Negrotto et al.   LEUKEMIA

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

(2010) O. Goodyear et al.   BLOOD

The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells

(2010) Maika Almstedt et al.   LEUKEMIA RESEARCH

Cancer/testis (CT) antigens: Potential targets for immunotherapy

(2009) Otavia L. Caballero et al.   CANCER SCIENCE

Intertumor and Intratumor NY-ESO-1 Expression Heterogeneity Is Associated with Promoter-Specific and Global DNA Methylation Status in Ovarian Cancer

(2008) A. Woloszynska-Read et al.   CLINICAL CANCER RESEARCH

The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma

(2008) Atsushi Natsume et al.   INTERNATIONAL JOURNAL OF CANCER